Clinical Trial Update: Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating pembrolizumab with eftilagimod alpha and radiotherapy in soft tissue sarcoma; the study is currently active and not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• eftilagimod alpha (eftilagimod alpha)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Neoadjuvant, Immunotherapy | Phase 2 | Status: ACTIVE_NOT_RECRUITING